Prognostic Value of VEGF in Human Pancreatic Ductal Adenocarcinoma.
- Author:
Yun Jeong LIM
1
;
Jong Kyun LEE
;
Cheol Keun PARK
;
Sang Yong SONG
;
Woo Young JANG
;
Hye Young HA
;
Dong Il PARK
;
Kyu Taek LEE
;
Seung Woon PAIK
;
Byung Chul YOO
;
Jong Chul RHEE
Author Information
1. Center for Health promotion, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Evaluation Studies
- Keywords:
VEGF;
Pancreatic neoplasm;
Prognosis
- MeSH:
Adolescent;
Adult;
Aged;
Biological Markers;
Carcinoma, Pancreatic Ductal/*metabolism/surgery;
Female;
Human;
Immunohistochemistry;
Male;
Middle Aged;
Pancreatic Neoplasms/*metabolism/surgery;
Prognosis;
Survival Analysis;
Vascular Endothelial Growth Factor A/*metabolism
- From:The Korean Journal of Internal Medicine
2004;19(1):10-14
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Since pancreatic cancer metastasizes early regardless of the size of the primary tumor, it is suggested that angiogenic factor is upregulated in this disease. Among the angiogenic factors, vascular endothelial growth factor (VEGF) is the most potent and specific growth factor. The aim of this study is to elucidate the prognostic value of VEGF expression in pancreatic cancers. METHODS: We analyzed the VEGF expression using immunohistochemistry in 72 resected pancreatic ductal adenocarcinomas. We examined the prognostic value of the VEGF expression along with its relationship with the clinicopathological features. RESULTS: VEGF expression and mutant p53 expression were not associated with microvessel density. VEGF expression was positively associated with mutant p53 expression. There were no statistically significant relationships between the VEGF expression and other clinicopathological features, such as age, sex, CA19-9, tumor size, location, tumor differentiation, and stage. VEGF expression was not associated with patient survival. CONCLUSION: VEGF expression was not associated with the microvessel density and patient survival in pancreatic ductal adenocarcinoma.
